In this study, it was aimed to evaluate AYC.2.2 agar for susceptibility testing of clinical isolates against first-line drugs. In the present study, 208 clinical isolates were tested on AYC.2.2 agar, which was previously validated for the first-line drugs isoniazid, rifampicin, streptomycin and ethambutol. Specificity, sensitivity, positive predictive value, negative predictive value and agreement for isoniazid-rifampicin-ethambutol-streptomycin were 100-100-97.2-99.3%, 94.8-94.8-79.3-94.3%, 100-100-82.1-98.03%, 97.03-98.03-96.7-98.08%, 98.07-98.5-94.7-98.07%, respectively. Results had shown that the newly developed AYC.2.2 agar promises as an alternative medium that can be used to perform susceptibility testing of isolates. However, further multicenter studies are needed to be used in routine mycobacteriology laboratories.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2217/fmb-2021-0032 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
High risk of drug-resistant tuberculosis in IGRA-negative contacts: should preventive treatment be considered?
Infection
January 2025
Department of Clinical Infectious Diseases, Research Center Borstel, Leibniz Lung Center, Parkallee 35, Borstel, Germany.
Purpose: Deciding whether to provide preventive treatment to contacts of individuals with multidrug-resistant (MDR) tuberculosis is complex.
Methods: We present the diagnostic pathways, clinical course and outcome of tuberculosis treatment in eight siblings from a single family. Tuberculosis disease was diagnosed by Mycobacterium tuberculosis culture and molecular detection of M.
Detection, characterization, and antibiotic resistance profiling of multidrug-resistant bacteria isolated from circulating currency in the Northeastern region of Bangladesh.
IJID Reg
March 2025
Department of Biochemistry and Molecular Biology, Shahjalal University of Science and Technology, Sylhet, Bangladesh.
Objectives: The study aims to investigate the prevalence of multidrug resistant bacteria on paper and coin currency obtained from various occupational groups in Bangladesh and to identify the bacterial species present. The research further seeks to evaluate the antibiotic resistance patterns of the identified bacterial isolates.
Methods: 84 paper currency notes and 56 coins were collected from seven different sources.
Genetic variability in strains isolated in a Japanese hospital.
IJID Reg
March 2025
Department of Bacteriology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Objectives: is a significant pathogen causing invasive meningococcal disease, posing clinical and public health concerns worldwide. This study aimed to investigate the genetic characteristics of clinical isolates at Okayama University Hospital in Japan.
Methods: Between 2018 and 2023, five clinical strains were isolated, of which three were subjected to the antimicrobial susceptibility testing and whole genetic analysis using MiSeq platform (Illumina, San Diego, CA, USA).
Nanobubble Ozone Stored in Hyaluronic Acid-Decorated Liposome Solutions: Inactivating Antibiotic-Resistant Bacteria and Genotoxicity, Sub-Acute and Sub-Chronic Toxicity Tests.
Infect Drug Resist
January 2025
Department of Medical Biochemistry, Faculty of Medicine, Bandırma Onyedi Eylül University, Bandırma/Balıkesir, Turkey.
Introduction: Nanobubble ozone stored in hyaluronic acid-decorated liposomes (patent application PCT/TR2022/050177) was used, and the Minimum Inhibitory Concentration (MIC) was found to be 1562 ppm. (patient isolate), (patient isolate), (MRSA) (ATCC12493), and (ATCC25922) bacteria, which are hospital-acquired and healthcare-associated infections, were used. A time-dependent efficacy study was conducted at 1600 ppm.
View Article and Find Full Text PDFCurrent methods for detecting and assessing HIV-1 antibody resistance.
Front Immunol
January 2025
Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Antiretroviral therapy is the standard treatment for HIV, but it requires daily use and can cause side effects. Despite being available for decades, there are still 1.5 million new infections and 700,000 deaths each year, highlighting the need for better therapies.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!